

# High Expression of PD-L1 is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition.

**Nishant Thakur**

Department of Hospital Pathology, The Catholic University of Korea, Republic of Korea

**Kwang Yeol Paik**

Department of Surgery, The Catholic University of Korea, Republic of Korea

**Gyoyeon Hwang**

Department of Hospital Pathology, The Catholic University of Korea, Republic of Korea

**Yosep Chong** (✉ [yichong@catholic.ac.kr](mailto:yichong@catholic.ac.kr))

Department of Hospital Pathology, The Catholic University of Korea <https://orcid.org/0000-0001-8615-3064>

---

## Research

**Keywords:** Programmed death-1, Programmed death ligand-1, Programmed death ligand-2, Re-currence, Disease-free survival, Overall survival

**Posted Date:** January 29th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-154339/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

# Abstract

## Background

Periampullary cancers (PACs) are characterised with tumour-infiltrating lymphocytes (TILs), severe fibrosis, and epithelial to mesenchymal transition (EMT). The immune checkpoint marker programmed death-1 (PD-1) and its ligands 1 and 2 have gained popularity in cancers with TILs. Evidence suggests a strong relationship between immune checkpoint markers and EMT in cancers. Here, we evaluated the expression and prognostic significance of immune checkpoint and EMT markers in PAC using an automated image analyser.

## Methods

Formalin-fixed, parafin-embedded surgically excised PAC tissues from laboratory archives (1998-2014) were evaluated by immunohistochemical staining for PD-1, PD-L1, and PD-L2 in a tissue microarray.

## Results

In total, 115 PAC patients (70 males and 45 female) with an average age of 63 years were analysed. Location, gross type, size, radial resection margin, N-M stage, lymphatic invasion, vascular invasion, peri-neural invasion, histologic well differentiation, severe inflammation, and high PD-L1 expression were significantly associated with recurrence. Higher PD-L1 expression, but not PD-1 and PD-L2, was significantly related to better overall survival (OS) and disease-free survival (DFS). PD-L1 and PD-L2 were significantly related to EMT markers.

## Conclusion

Aside from other clinicopathologic parameters, high PD-L1 expression was significantly related to better OS and DFS of PAC patients. Moreover, immune checkpoint markers were significantly associated with EMT markers. Therefore, PD-L1 expression can be a good prognostic marker to guide future immune target-based therapies in PAC patients.

# Background

Periampullary cancers (PACs), including pancreatic ductal adenocarcinoma, ampulla of Vater (AOV), and common bile duct (CBD) cancers, are highly lethal malignancies and predicted to be the second most common cause of cancer-related death after lung cancer by 2030 [1, 2]. The median 5-year overall survival (OS) rate is observed in less than 5% of patients; however, most patients die within a year after diagnosis owing to the invasive and metastatic nature of PACs [1]. Despite advancements in new chemotherapy protocols such as FOLFIRINOX or combination treatment with gemcitabine and nab-paclitaxel [3, 4], the survival rate of patients is poor for several reasons. The tumour microenvironment is characterised with profound desmoplasia, epithelial-mesenchymal transition (EMT), cancer stem cells, and immunosuppressive cell infiltrates, which seem to contribute to chemotherapeutic resistance [5, 6]. To date, there is no validated prognostic biomarker for therapeutic response; therefore, it is essential to identify a specific novel predictive biomarker that could help in clinical decision-making and development of better therapies for the management of PAC.

The immune checkpoint marker programmed death-1 (PD-1) and its ligands programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2) have attracted interest in the field of cancer immunology owing to conflicting prognostic significance [7]. The blockade of this pathway using specific inhibitors such as pembrolizumab and nivolumab could enhance the cytotoxicity of T cells in the tumour environment and substantially increase the long-term survival in different cancers [7-9]. However, in colon cancer and PAC, only patients with microsatellite instability-high (MSI-H) and mismatch repair deficiency can benefit from this treatment [10-12]. Furthermore, the prognostic significance of PD-L1 has been associated with poor survival in many solid cancers [13]. The results are conflicting in pancreatic cancer, as evident from the association of PD-L1 overexpression with poor OS in one study [14] and better OS in another report [15]. We hypothesised that these conflicting results on PD-L1 significance in cancers may be related to inter-observer and intra-observer variability between pathologists and different diagnostic assays, including specific antibody clone and staining platform. Nevertheless, the significance of PD-L2 expression has not been well investigated.

Recent evidence suggests a relationship between immune checkpoint markers and EMT. EMT is a multi-step process involving transition from epithelial to mesenchymal phenotype in response to chemoresistance and is important for cancer metastasis [16]. Many supporting studies have revealed the link between PD-L1 and EMT pathway. For instance, Alsuliman et al. demonstrated that EMT upregulated PD-L1 expression through the phosphoinositide 3-kinase/protein kinase B pathway in breast cancer [17]. Another study by Ock et al. showed that PD-L1 expression significantly downregulated E-cadherin and upregulated vimentin expression in head and neck squamous cancer cell lines. Using the Cancer Genome Atlas (TCGA) database, it was shown that patients with positive PD-L1 expression and EMT had worse prognosis than those with positive PD-L1 and negative EMT [18]. However, to the best of our knowledge, the relationship between immune checkpoint markers and EMT has not been explored in PAC.

In the present study, we used automated image analyser software to evaluate the expression of PD-1, PD-L1, and PD-L2 and their correlation with EMT markers in a tissue microarray (TMA) section of patients with PAC. We also scrutinised the correlation of these markers with clinicopathological features and determined their prognostic significance.

## Materials And Methods

### Patient enrolment

This study was approved by the Institutional Review Board of the Catholic University of Korea (SC19SESI0112). Surgically excised 115 PAC formalin-fixed paraffin-embedded tissues from Yeouido St. Mary's Hospital Laboratory Archives, Seoul, Korea, from 1998 to 2014 were obtained. Distal CBD, AOV, and pancreatic head cancers with periampullary involvement were extracted by pylorus-preserving pancreaticoduodenectomy or Whipple surgery, while duodenal cancers without ampullary or pancreatic involvement and intraductal papillary mucinous neoplasms considered as benign or premalignant lesions were excluded. None of the patients had experienced any preoperative chemotherapy treatment. A total of 115 patients with an average age of 63 years (range 36 to 82 years), including 70 men and 45 women, were enrolled in the study. The retrieved cases were blinded using sequential numbering. Y. C. and N. T. independently reviewed haematoxylin and eosin-stained slides to validate the original diagnosis. Cases with insufficient tissue samples were not included in the TMA analysis.

Clinicopathologic information, including age, sex, tumour location, gross type (fungating/polypoid, sessile, ulceroinfiltrative), TNM stage, tumour size (largest diameter), positive radial resection margin, lymphatic, vascular, perineural invasion, histologic differentiation (pancreaticobiliary vs. intestinal subtype, and well, moderately, poorly for each), degree of fibrosis and inflammation (mild, moderate, and severe for each), date of surgery, tumour recurrence, and date of death, were recorded. The degree of fibrosis was explained based on the four-tier system comprising < 10% (none), 10-33% (mild), 34-66% (moderate), and 67-100% (severe). The tumour epicentre was examined according to the staging system of the AJCC/Union International Contre le Cancer staging system 8th edition (AJCC/UICC).

Immunohistochemical staining for CK7, CK20, and CDX-2 was performed to determine pancreaticobiliary and intestinal subtypes. Radiological techniques such as position emission tomography and computed tomography (PET-CT) were performed and used along with changes in serum CA19-9 level to evaluate tumour relapse in patients with surgically resectable cancer. Incompletely resected cases with increasing tumour load were excluded from tumour recurrence, and death resulting from bile leakage bleeding, pulmonary embolism, and infection were not considered as cancer-related deaths. Patients with unspecified reasons for death were excluded from survival analysis. Data regarding the reason and date of death were collected based on the National Death Certificate data and therapeutic records from our institute. As National Death Certificate records have a year of postponement for information assortment, the death data of recent cases in 2013 and 2014 were documented based on our institutional medical records.

### TMA analysis

A Quick-Ray® Tissue Microarray recipient block (UB06-2, UNITMA Co., LTD., Seoul, Korea) was used to prepare nine TMA recipient blocks. Each case represented as three 2 mm sized tumour spots obtained from donor blocks to avoid tissue loss and edge artifact. Each recipient block comprised 45 cores of tumour tissues (15 cases), 4 cores of positive controls for stem cell markers, and 1 core of negative control. The recipient blocks were incubated at 30°C for 25 min to reduce tissue loss before core insertion. Normal umbilical cord for FGFR1, normal blood vessel for VEGF, and normal liver tissue for IGF1 were used as positive controls.

### Immunohistochemistry

The IHC procedure was similar to that used in our previous study. Formalin-fixed and paraffin-embedded TMA blocks were cut into 4 µm thick sections, dried in an oven at 70°C for 60 min, deparaffinised in xylene, and rehydrated in ethanol. Next, endogenous peroxidase activity was blocked by 3% hydrogen peroxide for 15 min, and antigen retrieval was performed by heating at 70°C for 1 h, followed by pre-treatment with cell conditioner 2 (pH 6) for 60 min. After 1 h of blocking with 5% normal goat serum, samples were incubated with respective antibodies at room temperature for 32 min, and then stained for 4 min with haematoxylin and the bluing agent. Samples were then subjected to chromogenic detection using ultraview universal DAB Detection Kit for min and a final washing step for 3 minutes. Balsamic acid was used to cover stained slides. Immunohistochemical staining for CK7, CDX-2, and CK20 was performed to classify tumours into pancreaticobiliary and intestinal subtypes. In addition, immunohistochemical staining was performed for immune cell markers such as PD-1, PD-L1, and PD-L2 and epithelial-mesenchymal transition markers, including IGF1, FGFR1, and VEGF.

The dilution and incubation conditions for each antibody were as follows: PD-1 (1:100, Cell Marque, CA, USA), PD-L1 (1:1000, Cell Marque, CA, USA), PD-L2 (1:1000, Cell Marque, CA, USA), CK7 (Prediluted, Ventana, Roche Diagnostics, USA), CDX-2 (Prediluted, Ventana, Roche Diagnostics, USA), CK20 (Prediluted, Ventana, Roche Diagnostics, USA), IGF1 (1:100, Abcam, CB4, UK), FGFR1 (ChIP Grade ab10646, 1:100, Abcam, CB4, UK), and VEGF (1:50, Quartett Immunodiagnostika, Berlin, Germany). A three-tier system (0, 1+, 2+, and 3+) was used to evaluate the immunoreactivity intensity score for each TMA core. If the intensity was high or low, the most frequently reported intensity was scored.

## Image analysis

We acquired 4-10 representative images of PD-1, PD-L1, and PD-L2 from the most strongly stained areas for each case and analysed using the US FDA-cleared image analysis system, GenAsis™ HiPath (Applied Spectral Imaging Ltd., USA) as per the manufacturer's instructions. The Korean FDA passed the Annual Quality Assurance program of the Korean Society of Pathologists for Image Analysis for Ki-67. Auto-white balancing was performed before capturing the image. Total and positive cells were counted using a three-tier classification system based on staining intensity using the default settings of the software (negative, 1+, 2+, and 3+; Figure 1). No manual pre-or post-processing adjustments were carried out.

## PD-1, PD-L1, and PD-L2 counting system

The following immunoreactivity scoring system is summarised in Table 1. For PD-1, one scoring system was used as follows: 0, 1P+2P+3P < 1%; 1, 1P+2P+3P < 10%; and 2, 1P+2P+3P ≥ 10%. Two scoring systems were used for PD-L1, and each type was further divided into three classes as follows: PD-L1 score 1 (1: 2P+3P < 50%; 2: 2P+3P < 90%; 3: 2P+3P ≥ 90%); PD-L1 score 2 (1: 1P+2P+3P < 90%; 2: 1P+2P+3P < 99%; 3: 1P+2P+3P ≥ 99%). Likewise, two scoring systems were used for PD-L2. Each type was further divided into four subtypes as follow: PD-L2 score 1 (0: 2P+3P < 1%, 1: 2P+3P < 10%, 2: 2P+3P < 50%, 3: 2P+3P ≥ 50%) and PD-L2 score 2 (0: 1P+2P+3P < 1%, 1: 1P+2P+3P < 10%, 2: 1P+2P+3P < 50%, 3: 1P+2P+3P ≥ 50%) (Table 1).

## Statistical analysis

R language version 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria) and T&F program version 3.0 (YooJin BioSoft, Korea) were used for all statistical analyses. Data are expressed as sample numbers and percentages. When subtypes of markers were regarded as ordinal variables, Spearman correlation analysis was performed to reveal the linear relationship between markers. In addition, the association between subtypes of markers was analysed using the Fisher's exact test. Kaplan-Meier survival curve analysis was performed to test OS and DFS; results with P<0.05 were considered statistically significant. Furthermore, Cox proportional hazard regression analysis was performed to analyse the effect of each independent variable, including markers on survival. Death events with OS time and recurrence events with DFS time were used in the survival analysis. To analyse the independent effect of input variables, multivariable analysis was performed using a backward stepwise variable elimination procedure as a variable selection method to minimise Akaike Information Criterion (AIC). A significance level of 0.1 was used in the univariable analysis to select initial input variables for the multivariable analysis.

## Results

### Patient characteristics

The clinicopathologic data of the enrolled patients are summarised in Table 2. The age of the patients ranged from 36 to 82 years (mean age 63 years). Of the 115 patients, 70 were male and 45 were female (M: F = 1.52:1) (Table 2). In gross type, 20 cases (17.4%) were classified as fungating type, 83 (72.2%) as infiltrative, 3 (2.6%) as ulcerofungating, 4 (3.5%) as sessile, and 2 (1.7%) as solid type. The mean tumour size was 3.2 cm (range 0.6 to 8.0 cm). All cases were stratified into two groups based on tumour size as follows: 88 cases (76.5%) in < 4.5 cm group and 27 cases (23.5%) in > 4.5 cm group. The N stage was divided into various groups according to the American Joint Cancer Committee (AJCC) staging system as follows: 66 cases (57.4%) were N0, 49 were N1 (42.6%), and none of the cases were found in N2. Moreover, within the M stage, 107 cases (93.7%) were M0 and 8 cases (6.9%) were M1. In addition, we observed lymphatic invasion in 51 cases (44.3%), vascular invasion in 14 cases (12.2%), perineural invasion in 67 cases (57.3%), positive radial resection margin in 8 cases (6.9%), and tumour ulceration in 9 cases (7.8%). Histologic grade revealed 30 cases (26.1%) as well-differentiated tumours, 81 (70.4%) as moderately differentiated tumours, and 4 as (3.5%) poorly differentiated tumours. In histologic subtypes, 30 cases (26.1%) were of the pancreaticobiliary subtype, 54 (46.9%) were prone to pancreaticobiliary subtype, 16 (13.9%) were prone to intestinal subtype, and 14 cases (12.1%) were intestinal subtype. Fibrosis was absent in 4 cases (3.5%) and was considered as mild, moderate, and severe in 20 (17.4%), 64 (55.6%), and 27 (23.5%) cases, respectively. The degree of inflammation was mild in 39 cases (33.9%), moderate in 63 cases (54.8%), and severe in 13 cases (11.3%). Tumour recurrence was observed in 52 cases (45.2%) during an average follow-up of 969.7 days (range, 3-5234 days). The average disease-free survival (DFS) duration was 731.2 days (range, 3-4173 days). Of the 115 patients, seven (6.8%) died during the follow-up.

### Immunohistochemical staining and immunoreactivity for immune checkpoint and EMT markers

The conditions for immunohistochemical staining are outlined in Table 3, while the representative images are shown in Supplementary Fig. 1. During the analysis of immune checkpoint markers, the immunoreactivity of PD-1 was 1+ in 97 cases (85.1%), 2+ in 11 cases (9.6%), and 3+ in 4 cases (5.3%). PD-L1 score 1 staining of 1+ was observed in 10 cases (8.8%), 2+ in 52 cases (45.6%), and 3+ in 52 cases (45.6%), while PD-L1 score 2 was 1+ in 24 cases (21.1%), 2+ in 44 cases (38.6%) and 3+ in 46 cases (40.3%). PD-L2 score 1 staining was negative in 21 cases (18.4%), 1+ in 31 cases (27.2%), 2+ in 39 cases (34.2%), and 3+ in 23 cases (20.2%), and PD-L2 score 2 immunoreactivity was negative in 4 cases, 1+ in 14 cases (12.3%), 2+ in 34 cases (29.8%), and 3+ in 62 cases (54%). Evaluation of EMT markers showed that insulin-like growth factor 1 (IGF1)

staining was negative in 13 cases (11.3%), 1+ in 70 cases (60.9%), 2+ in 26 cases (22.6%), and 3+ in 6 cases (5.2%). Fibroblast growth factor receptor 1 (FGFR1) immunoreactivity was 1+, 2+, and 3+ in 7 (6.1%), 50 (43.5%), and 58 (50.4%) cases, respectively. Vascular endothelial growth factor (VEGF) immunoreactivity was 1+ in 17 cases (14.8%), 2+ in 71 cases (61.7%), and 3+ in 27 cases (23.5%) (Table 3).

#### **Association of immune checkpoint markers with other markers**

No significant relationship was observed between PD1 subtype and other stem cell and EMT markers in the Spearman rank correlation analysis as well as Fisher's exact test (data not shown). PD-L1 score 1 was significantly associated with VEGF ( $P=0.006$ ) in the Spearman rank correlation analysis, but not in Fisher's exact test. Furthermore, we failed to observe any direct correlation between PD-L1 score 2 and any markers using both tests IGF1 ( $P<0.001$ ) and FGFR ( $P<0.001$ ) were significantly associated with PD-L2 score 1 in the Spearman rank correlation analysis, while IGF1 ( $P=0.002$ ), FGFR ( $P<0.001$ ), and VEGF ( $P=0.010$ ) showed significant correlation with PD-L2 score 1 in the Fisher's exact test. Further, IGF1 ( $P<0.001$ ), FGFR ( $P<0.001$ ), and VEGF ( $P=0.003$ ) were significantly correlated with PD-L2 score 2 in both tests (data not shown).

#### **Association of immune checkpoint markers with clinicopathological parameters related to the OS of PAC patients**

Kaplan-Meier test results revealed the significant association between OS and clinical parameters such as lower T7 stage ( $P<0.001$ ), AOV location ( $P<0.001$ ), sessile and solid Gross type ( $P<0.001$ ), size less than 4.5 ( $P=0.029$ ), lower N stage ( $P<0.001$ ), and lower M stage ( $P<0.001$ ). Other clinical parameters were not significantly associated with OS (Supplementary Figure 2). Among the pathological parameters, no lymphatic invasion ( $P<0.001$ ), no vascular invasion ( $P=0.003$ ), no perivascular ( $P<0.001$ ), histological differentiation ( $P=0.007$ ), histological intestinal subtype ( $P=0.002$ ), and no fibrosis ( $P=0.001$ ) were significantly associated with OS (Supplementary Figure 3). In addition, immunohistochemistry (IHC) markers such as CK20; 3+; ( $P=0.029$ ), CDX2 (3+;  $P<0.001$ ), FGFR (3+;  $P<0.001$ ), and VEGF (3+;  $P=0.03$ ) were significantly associated with OS (Supplementary Figure 4). Among immune cell markers, only PD-L1 (score 1:3,  $P=0.05$ ; score 2:3,  $P=0.009$ ; and score 2:3,  $P=0.002$ ), but not PD-1 and PD-L2 (data not shown), were significantly associated with OS (Figure 1 a, b, and c).

In the univariate analysis, location ( $P<0.001$ ), gross type ( $P=0.013$ ), size ( $P<0.001$ ), N1 stage ( $P<0.001$ ), M stage ( $P<0.001$ ), lymphatic invasion ( $P<0.001$ ), perineural invasion ( $P<0.001$ ), vascular invasion ( $P=0.004$ ), histological differentiation ( $P=0.01$ ), degree of inflammation (severe vs. mild:  $P=0.036$ ), histologic subtype ( $P=0.004$ ), CK7 (3+ vs. 0;  $P=0.045$ ), CK20 ( $P=0.039$ ), CDX2 ( $P=0.002$ ), FGFR ( $P=0.003$ ), and VEGF ( $P=0.037$ ) were significantly associated with OS (Supplementary Table 1). Among the immune checkpoint markers, only PD-L1 score 2 ( $P=0.012$ ) showed significant association with OS (Supplementary Table 1).

In the multivariate analysis using Cox regression model, location ( $P<0.001$ ), N stage ( $P=0.001$ ), M stage ( $P=0.004$ ), FGFR ( $P=0.004$ ), and PD-L1 score 2 (3+ vs. 1+ or 2+,  $P=0.019$ ) were independent prognostic factors of OS in patients with PAC (Supplementary Table 2).

#### **Association of immune checkpoint markers with DFS in recurrent patients**

We performed Kaplan-Meier test and found that only clinical parameters such as location of AOV ( $P=0.006$ ), size less than 4.5 cm ( $P=0.045$ ), and lower N stage ( $P<0.001$ ) were significantly correlated with better DFS (Supplementary Figure 5). Pathological markers such as no lymphatic invasion ( $P<0.001$ ), histological well differentiation ( $P<0.001$ ), and no fibrosis ( $P=0.005$ ) failed to show any significant association with better DFS (Supplementary Figure 6). Among IHC markers, CDX2 (3+;  $P=0.025$ ) and FGFR (3+;  $P=0.007$ ) were significantly associated with better DFS (Supplementary Figure 7). Further, PD-L1 (score 2:3,  $P=0.027$  and score 2:3,  $P=0.009$ ) was associated with better DFS (Figure 1 d, e).

Univariate analysis using the Cox regression model revealed the significant relationship between age ( $P=0.042$ ), location ( $P<0.008$ ), gross type (infiltrative vs. fungative:  $P=0.049$ ), size ( $P=0.009$ ), N1 stage ( $P=0.001$ ), lymphatic invasion ( $P<0.001$ ), histologic grade ( $P=0.003$ ), histologic subtype (intestinal subtype vs pancreaticobiliary subtype;  $P=0.031$ ), CDX2 ( $P=0.035$ ), and FGFR ( $P=0.01$ ) with better DFS (Supplementary Table 3). Among the immune checkpoint markers, only PD-L1 score 2 ( $P=0.032$ ) was related to better DFS (Supplementary Table 3).

We performed multivariable Cox proportional hazard regression analysis and found age ( $P=0.01$ ), lymphatic invasion ( $P<0.001$ ), and PD-L1 score 2 (3+ vs. 1+ or 2+;  $P=0.014$ ) as independent prognostic factors of DFS in patients with PAC (Supplementary Table 4).

## **Discussion**

In our study, we used automated image analyser software to count PD-1, PD-L1, and PD-L2 and found higher PD-L1 expression to be significantly related to better OS and DFS in patients with PACs. Immune checkpoint markers were significantly associated with EMT markers. We also validated the significant relationship between OS, DFS, and the previously established clinicopathological prognostic markers, pathological prognostic markers, and IHC markers such as CK20 and CDX2, as previously reported [1, 19].

In the present study, higher PD-L1 expression was significantly correlated with better OS and DFS in periampullary/pancreatic cancer patients. PD-L1 plays a major role in the maintenance and control of immune surveillance. Most cancer cells progress by avoiding immune surveillance through PD-L1 overexpression [20, 21]. Hence, it is natural to discover PD-L1 association with prognosis. However, there are conflicting results on

the prognostic significance of PD-L1 in different cancers. Researchers have studied the prognostic significance of PD-L1 in cancers and revealed conflicting results depending on cancer types. For instance, PD-L1 expression is associated with worse OS in multiple solid tumours, including breast cancer [22], lung cancer [23], colorectal cancer [24], cervical cancer [25], and hepatocellular carcinoma [26]. However, the prognostic significance of PD-L1 is inconsistent and conflicting in patients with PAC because higher PD-L1 expression was significantly associated with poor OS ( $P=0.016$ ) and progression-free survival [14, 27] as well as better OS and DFS [15, 28].

The difference in the prognostic value of PD-L1 in previous studies may be associated with the use of different antibody clones and IHC interpretation criteria. In terms of variability in antibody clones, the positivity of SP263 (durvalumab) assay was slightly higher than that of 22C3 pharmDx (pembrolizumab) at the centre of tumours and invasive margins of 379 TMA gastric cancer [29]. Similarly, PD-L1 staining was investigated in lung cancer cells using four antibody clones, which showed different PD-L1 patterns [30].

Many researchers and practicing pathologists have been claiming variable and complex interpretation criteria according to the clones and the possibility of inter- and intra-observer variability in the interpretation of PD-L1. To date, different cut-off values have been used to interpret IHC results across organs based on antibody clones in all pancreatic cancer studies. Moreover, there is not enough evidence that PD-L1 scoring based on a certain clone can substitute the results of other clones. Only one study has reported inter- and intra-observer variability of PD-L1 expression using four clones, SP263, SP142, 22C3, and E1L3N, in head and neck, breast, and urothelial carcinomas. These authors showed a relatively high concordance between three clones. However, the total sample size was very small (less than 30 cases for each cancer) and the comparison was made between only three pathologists, which cannot exclude the possibility of publication bias. Thus, further evidence from more studies with larger samples is imperative [31]. Therefore, we used automated image analyser software to reduce subjectivity.

We found that immune checkpoint markers were significantly associated with EMT markers. PD-L1 was significantly associated with VEGF, while PD-L2 expression was related to IGF, FGFR, and VEGF markers. EMT is crucial for cancer cell progression, stemness, therapeutic resistance, and tumour immune evasion. Typical EMT markers that have been explored in solid cancers include Snail, ZEB1, E-cadherin, vimentin, N-cadherin, and more recently, FGFR, VEGF, and IGF. Association between expression of immune checkpoint and EMT markers has been reported in several cancers, including breast, lung, and head and neck cancers [32]. In lung cancer, PD-L1 score was positively associated with Snail and vimentin expression [33]. Similarly, higher PD-L1 expression was reported in mesenchymal breast cancer cell lines and associated with increased activation of ZEB1 or Snail [34]. The results of the present study are consistent with these findings [35].

We re-evaluated other previously well-established markers and found location of AOV, lower T stage, sessile gross type, size less than 4.5 cm, lower N stage, lower M stage, no lymphatic invasion, no vascular invasion, no perineural invasion, histological well differentiation, intestinal subtype, and no fibrosis to be significantly associated with OS, consistent with the results of previous studies. We also compared the 7<sup>th</sup> and 8<sup>th</sup> edition of T staging based on the AJCC cancer staging system but failed to notice any significant difference. The identification of tumour epicentres is one of the most crucial factors that can help in the characterisation of AOV, pancreatic, and CBD cancers. The AJCC 8<sup>th</sup> edition also relies on various size norms and can vary according to the location of the tumour. According to our study results, CK20 and CDX2 expression may be good prognostic markers and can serve as additional parameters to guide the pathologist during TNM staging.

Our study has a few limitations. First considering the rarity of this disease, the sample size included in this study was not satisfactory. Future investigations with more samples from other institutions might be warranted to generalise the findings of our results. Second, this was a retrospective study that could simply reveal the relationship between molecular markers. Additional studies using other techniques and markers are needed to scrutinise the detailed mechanism between PD-L1 and EMT pathways in PACs.

## Conclusions

In this study, we found that higher expression of PD-L1 was significantly related to better OS and DFS of patients with PAC. Moreover, immune checkpoint markers were significantly associated with EMT markers. Therefore, PD-L1 expression can be a good prognostic marker and could guide future immune target-based therapies in patients with PAC.

## Abbreviations

PAC: Periampullary cancer

AOV; ampulla of Vater

CBD; common bile duct

OS; overall survival

DFS; disease-free survival

EMT; epithelial-mesenchymal transition

PD-1; programmed death 1

PDL; programmed death ligand

TMA; tissue microarray

FGFR; fibroblast growth factor receptor

IGF1; insulin-like growth factor 1

VEGF; vascular endothelial growth factor

## Declarations

### Ethics Approval and Consent to Participate

This study was approved by the Institutional Review Board of the Catholic University of Korea (SC19SESI0112) with a waiver of informed consent because the samples used in this study are legitimate according to the Bioethic Law and the data and images in this study were entirely deidentified

### Consent for Publication

Not applicable.

### Competing Interest

The authors declare that they have no competing interest.

### Funding

This study was funded by a research grant from the Institute of Clinical Medicine Research, Catholic University of Korea, Yeouido St. Mary's Hospital.

### Authors' Contributions

Conceptualization, Y.C.; methodology, Y.C. and K.Y.P.; software, Y.C.; validation, N.T., G.H., and Y.C.; formal analysis, N.T., G.H., and Y.C.; investigation, N.T., G.H., and Y.C.; resources, Y.C.; data curation, N.T., G.H., and Y.C.; writing—original draft preparation, N.T.; writing—review and editing, N.T. and Y.C.; visualization, N.T. and Y.C.; supervision, Y.C.; project administration, Y.C.; funding acquisition, Y.C. All authors have read and agreed to the published version of the manuscript.

### Acknowledgment

I appreciate Prof. Tae Jung Kim for advising on the conceptualization and funding acquisition and Mr. Young Dong Seo for reviewing the style.

### Availability of Data and Material

The original dataset of this study is available at [https://www.researchgate.net/profile/Yosep\\_Chong](https://www.researchgate.net/profile/Yosep_Chong).

### Authors information

#### Affiliations

Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul 07345, Republic of Korea

Nishant Thakur, Gyoyeon Hwang, Yosep Chong,

Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul 07345, Republic of Korea

Kwang Yeol Paik

### Corresponding author

## References

1. Rosai J: Rosai and Ackerman's Surgical Pathology Vol1. 2004.
2. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. *CA: a cancer journal for clinicians* 2016, 66(1):7-30.
3. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *New England Journal of Medicine* 2013, 369(18):1691-1703.
4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardière C: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *New England Journal of Medicine* 2011, 364(19):1817-1825.
5. Liu Q, Liao Q, Zhao Y: Chemotherapy and tumor microenvironment of pancreatic cancer. *Cancer cell international* 2017, 17(1):68.
6. Zheng L, Xue J, Jaffee EM, Habtezion A: Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. *Gastroenterology* 2013, 144(6):1230-1240.
7. Sharpe AH, Pauken KE: The diverse functions of the PD1 inhibitory pathway. *Nature Reviews Immunology* 2018, 18(3):153-167.
8. Barbee MS, Ogunniyi A, Horvat TZ, Dang T-O: Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. *Annals of Pharmacotherapy* 2015, 49(8):907-937.
9. Akinleye A, Rasool Z: Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. *Journal of Hematology & Oncology* 2019, 12(1):92.
10. Oliveira AF, Bretes L, Furtado I: Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. *Front Oncol* 2019, 9:396-396.
11. Eso Y, Shimizu T, Takeda H, Takai A, Marusawa H: Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. *Journal of Gastroenterology* 2020, 55(1):15-26.
12. Sudoyo AW, Kurniawan AN, Kusumo GD, Putra TP, Rexana FA, Yunus M, Budiayati AD, Kurniawan D, Utama A, Utomo AR: Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression. *Asian Pac J Cancer Prev* 2019, 20(11):3421-3427.
13. Wu P, Wu D, Li L, Chai Y, Huang J: PD-L1 and Survival in Solid Tumors: A Meta-Analysis. *PLOS ONE* 2015, 10(6):e0131403.
14. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M *et al*: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. *Clin Cancer Res* 2007, 13(7):2151-2157.
15. Wang Y, Lin J, Cui J, Han T, Jiao F, Meng Z, Wang L: Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer. *Oncotarget* 2017, 8(6):9354-9365.
16. Lamouille S, Xu J, Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. *Nat Rev Mol Cell Biol* 2014, 15(3):178-196.
17. Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M, Ghebeh H: Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells. *Molecular Cancer* 2015, 14(1):149.
18. Ock C-Y, Kim S, Keam B, Kim M, Kim TM, Kim J-H, Jeon YK, Lee J-S, Kwon SK, Hah HJ *et al*: PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. *Oncotarget* 2016, 7(13).
19. Zhang S, Huang X, Tian Y, Aimaiti S, Zhang J, Zhao J, Chen Y, Wang C: Clinicopathologic characteristics, laboratory parameters, treatment protocols, and outcomes of pancreatic cancer: a retrospective cohort study of 1433 patients in China. *PeerJ* 2018, 6:e4893.
20. Zhang J-y, Yan Y-y, Li J-j, Adhikari R, Fu L-w: PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. *Frontiers in Pharmacology* 2020, 11(722).
21. Han Y, Liu D, Li L: PD-1/PD-L1 pathway: current researches in cancer. *Am J Cancer Res* 2020, 10(3):727-742.
22. Qin T, Zeng YD, Qin G, Xu F, Lu JB, Fang WF, Xue C, Zhan JH, Zhang XK, Zheng QF *et al*: High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. *Oncotarget* 2015, 6(32):33972-33981.
23. Zhou Z-J, Zhan P, Song Y: PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. *Translational Lung Cancer Research* 2015, 4(2):203-208.
24. Li Y, He M, Zhou Y, Yang C, Wei S, Bian X, Christopher O, Xie L: The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. *Frontiers in pharmacology* 2019, 10:139-139.
25. Gu X, Dong M, Liu Z, Mi Y, Yang J, Zhang Z, Liu K, Jiang L, Zhang Y, Dong S *et al*: Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer. *Cancer cell international* 2019, 19:146-146.
26. Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, Chin S, Chung JC, Kim HC, Lee MS, Baek M-J: Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. *Cancer Res Treat* 2017, 49(1):246-254.
27. Liang X, Sun J, Wu H, Luo Y, Wang L, Lu J, Zhang Z, Guo J, Liang Z, Liu T: PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay. *Diagnostic Pathology* 2018, 13(1):5.

28. Imai D, Yoshizumi T, Okano S, Uchiyama H, Ikegami T, Harimoto N, Itoh S, Soejima Y, Aishima S, Oda Y *et al*: The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. *Cancer Med* 2017, 6(7):1614-1626.
29. Park Y, Koh J, Na HY, Kwak Y, Lee K-W, Ahn S-H, Park DJ, Kim H-H, Lee HS: PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs. *Cancer Res Treat* 2020, 52(3):661-670.
30. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B *et al*: PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. *J Thorac Oncol* 2017, 12(2):208-222.
31. Downes MR, Slodkowska E, Katabi N, Jungbluth AA, Xu B: Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. *Histopathology* 2020, 76(2):191-200.
32. Jiang Y, Zhan H: Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. *Cancer Letters* 2020, 468:72-81.
33. Kim S, Koh J, Kim M-Y, Kwon D, Go H, Kim YA, Jeon YK, Chung DH: PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. *Human Pathology* 2016, 58:7-14.
34. Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, Weinberg RA: Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. *Cancer research* 2017, 77(15):3982-3989.
35. Chong Y, Thakur N, Paik KY, Lee EJ, Kang CS: Prognostic significance of stem cell/ epithelial-mesenchymal transition markers in periampullary/pancreatic cancers: FGFR1 is a promising prognostic marker. *BMC Cancer* 2020, 20(1):216.

## Tables

**Table 1. Scoring system for Immune checkpoint markers using an automated image analyzer.**

Scoring	PD1 Score	PD-L1		PD-L2	
		Score 1	Score 2	Score 1	Score 2
0				2P+3P < 1%	1P+2P+3P < 1%
1+	1P+2P+3P < 1%	2P+3P < 50%	1P+2P+3P < 90%	1% ≤ 2P+3P < 10%	1% ≤ 1P+2P+3P < 10%
2+	1% ≤ 1P+2P+3P < 10%	50% ≤ 2P+3P < 90%	90% ≤ 1P+2P+3P < 99%	10% ≤ 2P+3P < 50%	10% ≤ 1P+2P+3P < 50%
3+	1P+2P+3P ≥ 10%	2P+3P ≥ 90%	1P+2P+3P ≥ 99%	2P+3P ≥ 50%	1P+2P+3P < 50%

**Table 2. Summary of clinicopathological data of the enrolled cases**


Clinicopathologica parameter	No. (%)			
Age (yrs)	Ranged 36 ~ 82		Mean 63.0 ± 9.4	
Sex	Male 70, Female 45		M:F=1.52:1	
Location (tumor epicenter)				
AOV	32	(27.82%)		
Pancreatic head	38	(33.04%)		
Distal CBD	45	(39.13%)		
T stage	T7		T8	
Tis	1	(0.86%)	1	(0.86%)
T1	20	(17.39%)	25	(25.73%)
T2	28	(24.34%)	53	(46.08%)
T3	58	(50.43%)	29	(25.21%)
T4	8	(6.95%)	7	(6.08%)
Gross type	Fungating		20 (17.39%)	
	Infiltrative		83 (72.17%)	
	Ulcerofungating		3 (2.6%)	
	Sessile		4 (3.47%)	
	Solid		2 (1.73%)	
Tumor size	Ranged 0.6 ~ 8.0 cm		Mean 3.2 ± 1.6cm	
<4.5 cm	88	(76.53%)		
≥4.5 cm	27	(23.47%)		
N stage	N0		66 (57.40%)	
	N1		49 (42.60%)	
	N2		0 (0%)	
M stage	M0		107 (93.04%)	
	M1		8 (6.96%)	
	Absent		Present	
Lymphatic invasion	64	(55.65%)	51	(44.35%)
Vascular invasion	101	(87.82%)	14	(12.18%)
Perineural invasion	48	(41.73%)	67	(58.26%)
Positive radial resected margin	107	(93.04%)	8	(6.96%)
Tumor ulceration	106	(92.17%)	9	(7.83%)
Histologic grade				
Well differentiated	30	(26.08%)		
Moderately differentiated	81	(70.43%)		
Poorly differentiated	4	(3.47%)		
Histologic subtype				
Pancreaticobiliary subtype	30	(26.08%)		
Prone to pancreaticobiliary subtype	54	(46.95%)		
Prone to intestinal subtype	16	(13.91%)		

Intestinal subtype	14	(12.17%)
Degree of fibrosis		
Absent	4	(3.47%)
Mild	20	(17.39%)
Moderate	64	(55.65%)
Severe	27	(23.47%)
Degree of inflammation		
Mild	39	(33.91%)
Moderate	63	(54.78%)
Severe	13	(11.30%)
Tumor recurrence	Absent	Present
	56 (48.69%)	52 (45.21%)
Death	37 (32.17%)	78 (67.82%)
Follow-up duration (days)	Ranged 3 ~ 5234	969.7 ± 1135
Disease free survival (days)	Ranged 3 ~ 4173	731.2 ± 954.5

**Table 3.** Conditions of the immunohistochemical stains and the immunoreactivity of the immune checkpoint and EMT markers.

IHC markers	PD-1		PD-L1				PD-L2				IGF-1		FGFR		VEGF	
	Score 1	Score 2	Score 1	Score 2	Score 1	Score 2	Score 1	Score 2	Score 1	Score 2	No.	(%)	No.	(%)	No.	(%)
Vendor	Cell Marque		Cell Marque				Cell Marque				abcam		abcam		Quartett Immuno diagnostika	
Dilution	1:100		1:1000				1:1000				1:100		1:100		1:50	
Positive control	Tonsil		Tonsil				Tonsil				Normal liver		Normal umbilical cord		Blood vessel	
	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
0	-	-	-	-	-	-	21	(18.4)	4	(3.5)	13	(11.3)	-	-	-	-
1+	97	(85.1)	10	(8.8)	24	(21.1)	31	(27.2)	14	(12.3)	70	(60.9)	7	(6.1)	17	(14.8)
2+	11	(9.6)	52	(45.6)	44	(38.6)	39	(34.2)	34	(29.8)	26	(22.6)	50	(43.5)	71	(61.7)
3+	6	(5.3)	52	(45.6)	46	(40.3)	23	(20.2)	62	(54.4)	6	(5.2)	58	(50.4)	27	(23.5)
Total	114	(100)	114	(100)	114	(100)	114	(100)	114	(100)	115	(100)	115	(100)	115	(100)

## Figures



**Figure 1**

Kaplan-Meier plots on the relationship between immune cell markers and overall survival (OS) and disease-free survival (DFS) in the periampullary/pancreatic cancers patients . There was significant difference between PD-L1 and OS according to (A) PD-L1 (1+:3+ vs 1+:1+ or 2+) (B) PD-L1 (2+:3+ vs 2+:2+ vs 2+:1+), and (C) PD-L1 (2+:3+ vs 2+:1+ or 2+), while there was also significant relationship between PD-L1 and DFS according to (D) PD-L1 (2+:3+ vs 2+:2+ vs 2+:1+), and (E) PD-L1 (2+:3+ vs 2+:1+ or 2+).

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [TableS1S2S3S4.docx](#)
- [Supplementaryfigure1to7.pptx](#)